Skip to main content

Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

[widgetkit id="2" name="CC Highlights"]

Dual IO 2021 Year in Review

Benefits of Dual I-O Therapy in NSCLC and Malignant Pleural Mesothelioma

Mark A. Socinski, MD

Dual IO 2021 Year in Review

Four-Year Follow-Up Data for First-Line Nivolumab Combined with Ipilimumab in NSCLC: CheckMate-227

Dual IO 2021 Year in Review

First-Line Nivolumab plus Ipilimumab Combined with 2 Cycles of Chemotherapy in Patients with Stage IV/Recurrent NSCLC: 2-Year Update of CheckMate-9LA

Dual IO 2021 Year in Review

Durvalumab Alone or in Combination with Tremelimumab and Chemotherapy versus Chemotherapy Alone as First-Line Treatment for Metastatic NSCLC: POSEIDON Study

Dual IO 2021 Year in Review

Benefits of Dual Immune Checkpoint Inhibitor Therapy in Metastatic NSCLC

Mark A. Socinski, MD

AACR & ASCO 2021 - Midyear Review

2021 Midyear Review: Non–Small-Cell Lung Cancer

AACR & ASCO 2021 - Midyear Review

Phase 2 Study of DM-CHOC-PEN in Patients with NSCLC with Central Nervous System Involvement

AACR & ASCO 2021 - Midyear Review

Clinical Outcomes for Plasma-Based Genomic Profiling versus Tissue Testing in Advanced NSCLC (NILE)

AACR & ASCO 2021 - Midyear Review

Pooled Analyses of Immune-Related Adverse Events and Efficacy from IMpower130, IMpower132, and IMpower150

AACR & ASCO 2021 - Midyear Review

Anti–PD-L1 Therapy in Combination with Chemotherapy versus Immunotherapy Alone in First-Line NSCLC with PD-L1 Score 1% to 49%

1
2
3
4
5

Page 2 of 22
Results 11 - 20 of 219